This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human IL-4 R alpha / CD124 Protein, His Tag
catalog :
ILR-H5221
quantity :
50 ug, 1 mg
price :
280 USD, 1800 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
ILR-H5221
product name :
Human IL-4 R alpha / CD124 Protein, His Tag
quantity :
50 ug, 1 mg
price :
280 USD, 1800 USD
quantity & price :
$280/50ug,$1800/1mg
target :
IL-4 R alpha
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human IL-4 R alpha, His Tag (ILR-H5221) is expressed from human 293 cells (HEK293). It contains AA Met 26 - His 232 (Accession # NP_000409.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human IL-4 R alpha, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
IL-4 is a pleiotropic cytokine produced by activated Th2 cells and mast cells, and plays a pivotal role in immune responses. The effects of IL-4 are mediated after binding to high affinity receptor complexes present on hematopoietic as well as non-hematopoietic cells. Hematopoietic cellular responses to IL-4 are mediated by a high affinity receptor complex comprised of the 140 kDa IL4Rα (CD124)subunit and the 70 kDa common cytokine γc chain (CD132).
Interleukin 4 Receptor (IL4R) also known as CD124, IL4Rα and BSF receptor, is a type I cytokine receptor produced by activated Th2 cells and mast cells, and plays an important role in Th2-biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. A soluble form of the encoded IL4R protein can be produced by an alternate splice variant or by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. IL4R can alternatively associate with IL13Ra1 to form the type II receptor which is responsive to both IL4 and IL13. Interleukin-4 receptor has been shown to interact with SHC1.
References :
(1) Ikizawa, K., et al., 2000, Biochem. Biophys. Res. Commun. (UNITED STATES) 268 (1): 54–9.
(2) Kashiwada, M., et al., 2001, J. Immunol. (United States) 167 (11): 6382–7.
(3) Hage T., et al., 1999, Cell 97 (2): 271–81.
(4) Gessner,A. et al., 2000, Immunobiology. 201 (3-4): 285-307.
(5) WillsKarp, M., F.D. Finkelman, 2008, Sci. Signal. 1:pe55.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments